secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001628280-22-022271
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive appoints new CMO and adds independent director to Board
-----------------------------------------------------------------

- Appointed Kenneth Truitt, M.D. as Chief Medical Officer effective Sept 6, 2022.
- Dr. Truitt granted inducement option for 100,000 shares; vesting 25%/25%/50% over 3 years.
- Appointed Timothy E. Morris to Board (Class I) effective Aug 5, 2022, filling newly created seat.
- Mr. Morris receives 28,500 stock options vesting 1/3 annually; will serve on Audit Committee.
- Board Chair Santo Costa steps down from Audit Committee; Board size increased to seven.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828022022271/0001628280-22-022271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828022022271/aqst-20220810.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-022271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer